This article provides financial information for Associated Banc-Corp (LS:907145), specifically focusing on its net income from continuing operations. The report details the period, value, and percentage change for this financial metric. The included data is sourced from ICE Data Services, FactSet, American Bankers Association, and Quartr for SEC filings.

This article provides details on the average basic shares outstanding for Actelis Networks, Inc. (OTC:ASNS). It highlights the company's financial data available on TradingView, covering market overview, financials, community insights, forecasts, and seasonal trends for the stock.

This article provides a brief mention of the net income from continuing operations for Associated Banc-Corp (NYSE: ASB). It lists general financial information and directs users to market data services and other resources for detailed financial analysis. The content appears to be a stub or a data point within a larger financial platform.

The article focuses on Associated Banc-Corp (NYSE: ASB) and its net revenue after provisions. It indicates that the content is related to financial data and analysis for the company, accessible through TradingView's platform.

The article discusses the revenue per share for Norfolk Southern Corporation (NFS) on the Hannover Stock Exchange. It provides general financial information for the company, accessible through TradingView. The content is basic and primarily serves as a placeholder for financial data specific to revenue per share.

H.C. Wainwright analyst Robert Burns has raised the price target for Aktis Oncology (AKTS) from $30 to $33, maintaining a Buy rating. This decision is based on the expectation that the company's pipeline will advance and expand in the coming year. Aktis Oncology recently received FDA clearance for a Phase 1b trial of AKY-2519, a miniprotein radioconjugate targeting B7-H3, adding to its existing lead program AKY-1189.

American Airlines Group (AAL) stock has seen mixed performance recently, with a significant decline over the past five years. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 21.2% at its current price of approximately US$11.32, implying an intrinsic value of around $14.36 per share. However, its Price-to-Earnings (P/E) ratio of 67.34x is significantly higher than both the industry and its peer average, suggesting it is overvalued by this metric when compared to its "Fair Ratio" of 30.26x.

The Walt Disney Company is set to lay off up to 1,000 employees as part of its ongoing cost-cutting measures, primarily impacting the marketing division. This restructuring follows the appointment of Josh D'Amaro as CEO and a recent consolidation of marketing functions under a single leadership. The move aims to strengthen Disney's financial position, building on previous efficiency programs, including 7,000 layoffs in 2023.

The Schall Law Firm is investigating claims on behalf of investors of AIRO Group Holdings, Inc. (AIRO) for potential securities law violations. This investigation follows Airo's announcement of missed Q4 and full-year 2025 financial results and the abandonment of its air taxi business, which led to an almost 11.3% drop in share price. Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.

Labcorp Holdings Inc. (LH) is set to announce its fiscal first-quarter 2026 earnings before market open on Thursday, April 30. Analysts anticipate a profit of $4.10 per share, an increase from the previous year, and project continued EPS growth for fiscal years 2026 and 2027. Despite underperforming the S&P 500, LH has significantly outperformed the Health Care Select Sector SPDR ETF (XLV) over the past 52 weeks, and analysts maintain a "Strong Buy" rating with a target price indicating a 19% upside.